All In Biotech

NDA 019884 · Baxter Hlthcare

Mesnex

Mesna · Intravenous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 17, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 30, 1988

Approved uses

1

Original approval plus efficacy supplements

Registered trials

343

41 Phase 3, 44 recruiting

FAERS reports

8,485

8,228 serious, 1,763 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 10, 2025.

MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. MESNEX is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. ( 1 ) Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. ( 1 )

Mechanism: Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic metabolites and inhibits their effects on the bladder.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 30, 1988 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • MESNEX · MESNA 100MG/ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Mesna" as an intervention, any sponsor and status, largest first.

All 343 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia1,311
  • pyrexia713
  • off label use665
  • neutropenia587
  • anaemia411
  • thrombocytopenia402
  • vomiting387
  • nausea381
  • pancytopenia373
  • sepsis367
  • mucosal inflammation347
  • diarrhoea346

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004147
2005115
2006119
200787
2008139
2009137
2010190
2011368
2012338
2013249
2014244
2015342
2016337
2017311
2018567
2019607
2020640
2021722
2022623
2023589
2024655
2025608
2026351

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mesnex* (Mesna)

2024 spending

$690K

Beneficiaries

302

614 claims

Per beneficiary

$2,286

$76.34 per unit

View as table
YearSpending
2020$596,229
2021$544,970
2022$659,475
2023$707,838
2024$690,420

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 423 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.